The Rheumatoid Arthritis Diagnostic Tests Market is estimated to be valued at US$ 2,775.1 Mn in 2023 and is expected to exhibit a CAGR of 5.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Rheumatoid arthritis diagnostic tests help in the detection of autoantibodies and inflammation markers associated with rheumatoid arthritis. The common tests utilized for rheumatoid arthritis diagnosis include serological tests such as rheumatoid factor (RF) test and anti-cyclic citrullinated peptide (anti-CCP) test as well as imaging tests like magnetic resonance imaging (MRI) scans and ultrasounds. These tests aid in early diagnosis and effective management of rheumatoid arthritis.
The growth of the rheumatoid arthritis diagnostic tests market is driven by the rising prevalence of rheumatoid arthritis worldwide and increasing adoption of advanced serological testing methods. According to the Arthritis Foundation, around 1.3 million US adults are diagnosed with rheumatoid arthritis. Moreover, anti-CCP biomarker testing is gaining widespread acceptance over traditional RF tests owing to its higher specificity and sensitivity. Furthermore, 3D ultrasound and MRI techniques are offering novel insights into early disease pathogenesis and treatment responses, thus fueling the demand for imaging modalities in rheumatoid arthritis diagnosis.
The Rheumatoid Arthritis Diagnostic Tests market can be segmented based on test type into 5 categories- Serum Antibody Tests, Rheumatoid Factor Tests, Anti-CCP Antibody Tests, Erythrocyte Sedimentation Rate (ESR) Test, and C – reactive protein (CRP) Tests. Among these, the Anti-CCP Antibody Tests segment dominates the market with the highest market share. Anti-CCP antibodies are considered highly specific to rheumatoid arthritis and are detected only in 65-75% of rheumatoid arthritis patients. Their presence indicates a greater likelihood and severity of persistent rheumatoid arthritis.
- Political: Government initiatives to spread awareness about rheumatoid arthritis and increasing funding for research & development of new diagnostic tests are influencing the market growth.
- Economic: Rising per capita healthcare expenditure and improving reimbursement policies for diagnostic tests positively impact the market.
- Social: Growing geriatric population suffering from rheumatoid arthritis and increasing awareness regarding early diagnosis drive market expansion.
- Technological: Advancements in biosensors, microfluidics, and immunoassays are expanding testing capabilities and facilitating point-of-care testing. Miniaturized devices enable conducting multiple panels on a single platform.
The Global Rheumatoid Arthritis Diagnostic Tests Market Size is expected to witness high growth, exhibiting CAGR of 5.4% over the forecast period, due to increasing government initiatives for research funding and rising awareness regarding early diagnosis. North America dominated the market in 2023 with highest market share and is expected to maintain its lead over the forecast period owing to well-established healthcare infrastructure and high per capita healthcare spending. Key players operating in the Rheumatoid Arthritis Diagnostic Tests market are Abbott Diagnostics (Abbott Laboratories), Labcorp, Antibodies Inc., Networks LLC, Beckman Coulter, Inc., Euro Diagnostica AB, F. Hoffmann-La Roche Ltd., Qiagen NV, Siemens Healthcare GmbH. Regional analysis offered above provides a detailed sense of the various factors that are encouraging growth in the regional markets. The key players section provided additionally offer changed understanding of the most important players working in in the Rheumatoid Arthritis Diagnostic Tests market.